AzTrials
AzTrials

PolyneuropathiesNCT03617185

Effect of Exercise and Surgical Weight Loss on Polyneuropathy

A study testing High Intensity Interval Training (HIIT), Routine Exercise and Bariatric surgery in people with Polyneuropathies and Obesity, run by University of Michigan at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this research study is to evaluate how exercise and surgical weight loss affect how likely an individual is to develop peripheral neuropathy and other neurologic complications. Read more about this study

Who is it for?
Ages 40 years and older
What is being tested?
High Intensity Interval Training (HIIT), Routine Exercise and Bariatric surgery
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
140 participants
Where
1 siteUnited States
Study dates
27 Jul 2018to 1 Aug 2024
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Attending a bariatric surgery clinic
  • BMI > 35 with one comorbid condition present or BMI > 40 without comorbid conditions present
  • Willing and capable to sign the Institutional Review Board (IRB) approved consent form and cooperate with the medical procedures for the study duration
  • Willing to accept random treatment assignment to HIIT or routine exercise counseling

Who cannot join

  • History of distal symmetric polyneuropathy (DSP) from causes other than diabetes and/or the metabolic syndrome as determined through medical history, family history, history of medications, occupational history, history of exposure to toxins, physical and neurological examinations;
  • Use of warfarin, heparin, or other anticoagulants, which would increase the risk of complications from skin biopsy
  • Contraindication to HIIT participation including a failed exercise stress test
  • Participation in an experimental medication trial within 3 months of starting the study
  • Undergoing therapy for malignant disease other than basal-cell or squamous-cell skin cancer
  • Medical or psychiatric reason for not being a surgical candidate
  • Requiring a walking assist device;
  • Currently smoking

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University Of Michigan

    Ann Arbor, Michigan, 48109

Other trials in United States

About this study

Official title: The Effect of High Intensity Interval Training and Surgical Weight Loss on Distal Symmetric Polyneuropathy Outcomes

The purpose of this research study is to evaluate how exercise and surgical weight loss affect how likely an individual is to develop peripheral neuropathy and other neurologic complications.

Read the detailed description

The length of this study, including screening is approximately 24 months. Patients at Bariatric Surgery Clinics will be recruited for this study. Both patients that decide to undergo bariatric surgery, and those that do not undergo surgery will be enrolled. Patients will be randomized to either a high intensity interval training (HIIT) or standard exercise regimen after eligibility is confirmed and the baseline visit is complete. All patients will complete follow-up appointments at 3 month, 12 months and 24 months. Patients that are randomized to the HIIT program will compete 2 supervised and 1 unsupervised training sessions a week for 24 months.

Being tested
High Intensity Interval Training (HIIT), Routine Exercise, Bariatric surgery
Keywords
Metabolic syndrome, Exercise
Medical subject headings
Polyneuropathies, Obesity, Metabolic Syndrome, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High Intensity Interval Training (HIIT)Other

    Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.

  • Routine ExerciseOther

    Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).

  • Bariatric surgeryProcedure or surgery

    Patients will undergo bariatric surgery as part of their routine care

Study groups in NCT03617185
Study groupRoleWhat they receive
Bariatric Surgery/HIITActive comparatorPatients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
Receives: Other: High Intensity Interval Training (HIIT); Procedure: Bariatric surgery
Bariatric Surgery/Routine ExerciseActive comparatorPatients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
Receives: Other: Routine Exercise; Procedure: Bariatric surgery
No Bariatric Surgery/HIITActive comparatorPatients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
Receives: Other: High Intensity Interval Training (HIIT)
No Bariatric Surgery/Routine ExerciseActive comparatorPatients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
Receives: Other: Routine Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh

    Intraepidermal Nerve Fiber Density (IENFD) as assessed by 3mm skin biopsies at the proximal thigh.

    Measured: Baseline, 3 months, 12 months and 24 months

Secondary outcomes (34)
  1. Intraepidermal Nerve Fiber Density (IENFD) at Distal Leg.

    Intraepidermal Nerve Fiber Density (IENFD) as assessed by 3mm skin biopsies at the distal leg.

    Measured: Baseline, 3 months, 12 months and 24 months

  2. Corneal Confocal Microscopy (CCM) - Fiber Density

    Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.

    Corneal Nerve Fiber Density are quantified by fibers/mm2, a higher number represents a higher density of fibers. Lower numbers indicate worse neuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  3. Corneal Confocal Microscopy (CCM) - Branch Density

    Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.

    Corneal Nerve Branch Density are quantified by branches/mm2, a higher number represents a higher density of branches. Lower numbers indicate worse neuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  4. Corneal Confocal Microscopy (CCM) - Fiber Length

    Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.

    Corneal Nerve Fiber Length are quantified by mm/mm2, a higher number represents a higher total length of fibers. Lower numbers indicate worse neuropathy .

    Measured: Baseline, 3 month, 12 months and 24 months

  5. Corneal Confocal Microscopy (CCM) - Tortuosity Coefficient

    Non-invasive imaging technique of the corneal nerves to quantify nerve density and morphology.

    Tortuosity Coefficient represents the total tortuosity (twisting/bending of nerves). As a coefficient the value is unitless, a higher value represents greater tortuosity. Lower numbers indicate worse neuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  6. 24-2 Frequency Doubling Technology (FDT) - Mean Deviation

    24-2 FDT was used to evaluate retinopathy using visual field deficits. Mean Deviation is presented below.

    Mean deviation is the average difference from normal expected value in the patients' particular age group. Lower values indicate more visual deficit. Higher values indicate fewer visual deficit.

    Measured: Baseline, 3 month, 12 months and 24 months

  7. 24-2 Frequency Doubling Technology (FDT) - Foveal Sensitivity dB

    24-2 FDT was used to evaluate retinopathy using visual field deficits. Foveal sensitivity is presented below.

    Foveal sensitivity is the measurement of the fovea's light detection ability. Lower values suggest visual field deficits.

    Measured: Baseline, 3 month, 12 months and 24 months

  8. 24-2 Frequency Doubling Technology (FDT) - Pattern SD

    24-2 FDT was used to evaluate retinopathy using visual field deficits. Pattern SD (PSD) is presented below.

    PSD provides information about localized loss. A higher PSD indicates a non-uniform sensitivity loss and visual field deficit.

    Measured: Baseline, 3 month, 12 months and 24 months

  9. Retinal Fundus Photography

    As assessed by fundus photographs, participants were identified as either having retinopathy or not having retinopathy. Data is shown as number of people with retinopathy at a particular study visit.

    Measured: Baseline, 3 month, 12 months and 24 months

  10. Nerve Conduction Study (NCS) - Latency

    Latency measures the time in millisecond between stimulation and the recording electrode. Was performed on sural, peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.

    • Peroneal: 0 - No response, >6.5 - Abnormal
    • Sural: 0 - No response, >4.5 - Abnormal
    • Tibial: 0 - No response, >6.1 - Abnormal

    Measured: Baseline and 24 months

  11. Nerve Conduction Study (NCS) - Motor Amplitude

    Amplitude measures the height of electrical signal (waveform) in millivolts produced by the stimulated motor nerve. Was performed on peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.

    • Peroneal: 0 - No response, < 1.1 - Abnormal
    • Tibial: 0 - No response, <1.1 - Abnormal

    Measured: Baseline and 24 months

  12. Nerve Conduction Study (NCS) - Sensory Amplitude

    Amplitude measures the height of electrical signal (waveform) in microvolts produced by the stimulated sensory nerve. Was performed on sural nerve. No response and abnormal values indicate neuropathy.

    • Sural: 0 - No response, <4 - Abnormal

    Measured: Baseline and 24 months

  13. Nerve Conduction Study (NCS) - CV

    Conduction velocity (V) measures the speed (m/s) at which the electrical impulse travels along the nerve. Was performed on peroneal nerves. No response and abnormal values indicate neuropathy. Abnormal values are <36 or 39, depending on whether certain criteria applied to the participant. Data was not analyzed separately.

    Measured: Baseline and 24 months

  14. Nerve Conduction Study (NCS) - F Wave Index

    F wave index measures the time in millisecond between stimulation at a distal (near the muscle) point and for the stimulus to travel to the spinal cord and back, allowing to assess the entire length of the nerve.

    Was performed on peroneal, and tibial nerves. No response and abnormal values indicate neuropathy.

    • Peroneal: 0 - No response, >55 - Abnormal
    • Tibial: 0 - No response, >55 - Abnormal

    Measured: Baseline and 24 months

  15. Cardiac Autonomic Neuropathy Testing-Deep Breathing/Exhalation to Inhalation (E:I) Ratio

    Deep breathing/exhalation to inhalation (E:I) ratio were evaluated using PS monitor software. Values < 1 are abnormal, indicative of cardiovascular autonomic neuropathy

    Measured: Baseline and 24 months

  16. Cardiac Autonomic Neuropathy Testing (30:15 Ratio)

    Postural change-30:15 ratio was evaluated using PS monitor software. Values < 1 are abnormal, indicative of cardiovascular autonomic neuropathy

    Measured: Baseline and 24 months

  17. Cardiac Autonomic Neuropathy Testing (Valsalva Ratio)

    Valsalva ratio was evaluated using PS monitor software. Values <= 1.10 are abnormal, indicative of cardiovascular autonomic neuropathy

    Measured: Baseline and 24 months

  18. Participants With Probable Polyneuropathy as Defined by the Toronto Definition of Probable Neuropathy

    Toronto definition of probable neuropathy is having at least 2 out of 3 of the following: abnormal sensory examination, reflexes, and patient-reported symptoms. Data is reported as number of participants who, under the Toronto definition, were identified as having probable polyneuropathy.

    Measured: 24 months

  19. Michigan Neuropathy Screening Instrument (MNSI)

    MNSI questionnaire is scored from 0-15, score > 4 indicate neuropathy, higher scores indicate worse neuropathy.

    A score of 1 point is given for answers of "yes" for questions 1-6, 8-12, 14, and 15 and "no" for questions 7 and 13.

    Measured: Baseline, 3 month, 12 months and 24 months

  20. Michigan Neuropathy Screening Instrument (MNSI) - Exam

    MNSI exam is scored from 0-8, score >= 2.5 indicate neuropathy. Higher scores indicate worse neuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  21. Michigan Neuropathy Screening Instrument (MNSI) - Index

    The Michigan Neuropathy Screening Instrument (MNSI) index is a weighted composite score computed using the sum of the b-coefficients for all items within the MNSI questionnaire (15 questions) and MNSI exam (4 physical/visual exam).

    Range: -0.93, 7.39 Values > 2.5407 are indicative of clinical neuropathy

    Measured: Baseline, 3 month, 12 months and 24 months

  22. Utah Early Neuropathy Score (UENS)

    UENS is a composite score with five sections measuring multiple clinical measures of nerve injury. Sections are scored separately for each side (Right vs Left), and the total score is the sum across everything. Range: 0-42, higher score represents more severe polyneuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  23. Modified Toronto Neuropathy Score (mTNS)

    mTNS is a scale of 0-33 that measures neuropathy symptoms and exam findings. Higher scores indicate more severe polyneuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  24. Survey of Autonomic Symptoms (SAS)

    SAS evaluates the presence and magnitude of autonomic symptoms. Total impact score ranges from 0-60 (or up to 55 for participants to whom certain criteria did not apply). Higher score indicates worse autonomic neuropathy

    Measured: Baseline, 3 month, 12 months and 24 months

  25. Diabetic Neuropathy Score (DNS)

    DNS is a questionnaire of neuropathy symptoms. Score ranges 0-4, >/=1 indicates polyneuropathy. 0 indicates no polyneuropathy.

    Measured: Baseline, 3 month, 12 months and 24 months

  26. Short Form McGill Pain Questionnaire

    Sum of the sensory score (0-30) and affective score (0-15) for a total score of 0-45. A higher score represents greater pain present.

    Measured: Baseline, 3 months, 12 months, 24 months

  27. Numerical Rating Scale for Pain

    Participant reported pain scale with range 0-10, higher score indicates more pain.

    Measured: Baseline, 3 months, 12 months, 24 months

  28. Neuropathy Quality of Life (NeuroQOL)

    Neuropathy Quality of Life (NeuroQOL) evaluates symptoms and function in regard to quality of life over the past four weeks. Range 1-15, higher score indicates neuropathy having a greater impact on quality of life.

    Measured: Baseline, 3 months, 12 months, and 24 months

  29. 8 Foot Get Up and Go Test

    This test measures in seconds how long it takes the participant to stand up from a seated position, walk around a cone places 8 feet away, and return to the chair and sit down. Less time indicates better speed, agility, and balance when moving.

    Measured: Baseline, 3 months, 12 months, and 24 months

  30. Berg Balance Scale

    Berg Balance Scale measures participants' ability to balance and avoid falls. Scores range from 0-56, higher score indicates less likely to fall.

    Measured: Baseline, 3 months, 12 months, and 24 months

  31. Modified Falls Efficacy Scale - Fall Evaluation

    Patient response indicating if they have fallen in the last year. Data is shown as number of people who have fallen in the last year.

    Measured: Baseline, 3 months, 12 months, and 24 months

  32. Neurothesiometer

    Neurothesiometer is placed on the bottom of the great toe, and slowly increased until participant reports they can feel the vibration. The greater the microns, the less feeling the participant has, suggestive of worse sensory function.

    Value > 25 Microns is indicative of neuropathy. There is no known maximum range. Lower values indicate better sensory function.

    Measured: Baseline, 3 months, 12 months, and 24 months

  33. NIH Toolbox Cognitive Battery

    NIH Toolbox Cognition Fluid (Range: 0-100) - Composite score derived as an average across five cognitive domains.

    It's a fully adjusted T-score comparing the participant to a nationally representative sample, stratified by age and other demographics.

    Individual domain scores are fully adjusted T score with range 0-100 and measures the following-

    • Inhibitory Control and Attention - executive function, attention .
    • Dimensional Change Card Sort - executive function
    • Picture Sequence Memory - episodic memory
    • List Sorting Working Memory - working memory
    • Pattern Comparison - processing speed

    A T-score of 50 represents the population mean. A score of 60 indicates that the participant is 1 SD above the national average for individuals with similar demographic characteristics

    Higher scores reflect better cognitive functionality. No set clinical threshold, scores above mean indicate above average cognition for a given age group.

    Measured: Baseline and at 24 months

  34. Rey Auditory Verbal Learning Test

    Used to evaluate verbal learning and memory using a list of 15 unrelated words presented to the participant over repeat trial.

    Includes 3 independent scales:

    • Auditory Learning (Total recall) - Measures memory and learning ability. Raw score range (0- 75)
    • Delayed Recall - Measures long term memory retention. Raw score range (0-15)
    • Recognition - Measures ability to recognize previously learned information. Raw score range (0-15).
    • Raw scores were converted to age-standardized Z-scores using 10-year age bands (e.g., 20-29, 30-39, 40-49, etc.), with a mean of 0 and standard deviation of 1.
    • A Z-score of 0 represents the population mean
    • For each scale, scores above 0 are better. Standard deviations above the mean indicates a better learning and memory ability for a given age group.

    No set clinical threshold, scores above mean indicate above average cognition for a given age group.

    Measured: Baseline and at 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2018
  2. Study start27 Jul 2018
  3. Primary completion1 Aug 2024
  4. Study completion1 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients will be assigned to one of 4 arms, bariatric surgery/HIIT, bariatric surgery/routine exercise, no bariatric surgery/HIIT, no bariatric surgery/routine exercise.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
140 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03617185
Sponsor's protocol ID
HUM00143541
Other IDs
1R01DK115687-01A1
Status last verified
Sep 2026
First submitted
14 Jul 2018
Last updated
17 Sep 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Reynolds EL, Koenig F, Watanabe M, Kwiatek A, Elafros MA, Stino A, Henderson D, Herrmann DN, Feldman EL, Callaghan BC. Comparison of intraepidermal nerve fiber density and confocal corneal microscopy for neuropathy. Ann Clin Transl Neurol. 2024 Dec;11(12):3115-3124. doi: 10.1002/acn3.52218. Epub 2024 Oct 12.

    PubMed 39394845

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in